Hansoh Pharmaceutical Group Co Limited/ADR
HNSPFDrugs in Pipeline
16
Phase 3 Programs
10
Upcoming Catalysts
6
Next Catalyst
Apr 28, 2026
14dMarket Overview
Stock performance and key metrics
6 upcoming, 0 past
HS-10374 Phase 2 Results Expected
Primary completion for HS-10374 trial (NCT06176508) in Psoriatic Arthritis
Source5 more catalysts beyond 14 days
Start a 48h free trial to see all upcoming catalysts
Pegol-Sihematide
Chronic Kidney Diseases
Flumatinib 600mg qd
CML, CML-CP,MMR,TKI
Almonertinib
Non-small Cell Lung Cancer
HS-20117
Non-Squamous Non-Small Cell Lung Cancer
HS-10234
Chronic HBV Infection
HS-20094 injection
Overweight
HS-20093
Advanced Solid Tumor
Aumolertinib
Non-small Cell Lung Cancer
HS-20089
Ovarian Cancer
Topotecan
Small Cell Lung Cancer
PEG-Tα1
Hepatitis B, Chronic
HS-10370
Advanced Solid Tumor
HS-20094 5mg
Type 2 Diabetes
iloperidone
Schizophrenia
HS-10374
Psoriatic Arthritis
HS-10516 + Lenvatinib
Advanced Clear Cell Renal Cell Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Pegol-Sihematide | Phase 3 | Chronic Kidney Diseases | - | - |
Flumatinib 600mg qd | Phase 3 | CML, CML-CP,MMR,TKI | - | - |
Almonertinib | Phase 3 | Non-small Cell Lung Cancer | - | - |
HS-20117 | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
HS-10234 | Phase 3 | Chronic HBV Infection | - | - |
HS-20094 injection | Phase 3 | Overweight | - | - |
HS-20093 | Phase 3 | Advanced Solid Tumor | - | - |
Aumolertinib | Phase 3 | Non-small Cell Lung Cancer | - | - |
HS-20089 | Phase 3 | Ovarian Cancer | - | - |
Topotecan | Phase 3 | Small Cell Lung Cancer | - | - |
PEG-Tα1 | Phase 2 | Hepatitis B, Chronic | - | - |
HS-10370 | Phase 2 | Advanced Solid Tumor | - | - |
HS-20094 5mg | Phase 2 | Type 2 Diabetes | - | - |
iloperidone | Phase 2 | Schizophrenia | - | - |
HS-10374 | Phase 2 | Psoriatic Arthritis | - | - |
HS-10516 + Lenvatinib | Phase 2 | Advanced Clear Cell Renal Cell Carcinoma | - | - |